

## Information about proposed Board of Directors Annual General Meeting 2016

---

### ***Proposal for re-election of the current members of the board of directors:***

#### **Annette Clancy**

Born 1954.

Board member since 2014.

B.Sc. Hons Pharmacology, from Bath University UK.

*Other assignments:* Non executive Chairman of the Board of the three private European biotechnology companies Genable Technologies Ltd., Obseva SA and Lysogene. Senior European Advisor to the Biopharmaceutical Team of Frazier Healthcare Ventures, for whom she provides strategic advice on both new and existing investments. Ms. Clancy has over 30 years of experience in the Pharmaceutical/Biopharm Industry, working in a variety of functions (R&D, Commercial, Worldwide Business Development) in the US and UK.

*Previous appointments:* Head of Transactions and Alliance Management at GlaxoSmithKline (GSK) where she was responsible for executing major transactions ranging from early drug discovery partnerships, to global commercial alliances as well as Mergers and Acquisitions until her retirement in 2008. Non-Executive Board Director to Silence Therapeutics plc. (2008-2012) and Clavis Pharma in Norway (2010-2013).

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

#### **Matthew Gantz**

Born 1965.

Board member since 2012.

B.A. from Princeton University and MBA from Harvard Business School.

*Other assignments:* Executive Vice President of BTG, an international specialist healthcare company.

*Previous assignments:* Founder and previously CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Lennart Johansson**

Born 1955.

Board member since 2010.

M.Sc. from Stockholm School of Economics.

*Other assignments:* Member of the management team and Senior Advisor in Patricia Industries (a division of Investor AB). Board member of Hi3G, Chairman of the Board of Vectura AB and deputy Board member of Mölnlycke Health Care.

*Previous assignments:* CEO of b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB, Gambro Holding AB. Member of Investor AB management team.

*Shares:* 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Helena Saxon**

Born 1970.

Board member since 2011.

M.Sc. from Stockholm School of Economics.

*Other assignments:* CFO of Investor AB. Member of the Board of SEB.

*Previous assignments:* CFO of Hallvarsson & Halvarsson, Vice President of Investor AB and financial analyst at Goldman Sachs. Board member of Aleris, Gambro and Mölnlycke Health Care.

*Shares:* 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Hans GCP Schikan**

Born 1958.

Board member since 2011.

Pharm.D. from Utrecht University.

*Other assignments:* Chairman of the Board of Asceneuron in Switzerland, InterNA in the Netherlands and Complix in Belgium. Board member of Hansa Medical and Wilson Therapeutics in Sweden, and the Dutch Top Sector Life Sciences & Health in the Netherlands. Advisor to various organisations in the Life Science sector.

*Previous appointments:* CEO of Prosensa and member of Prosensa's Supervisory Board. Board member of Top Institute Pharma. Chairman of Nefarma, the association for innovative medicines in the Netherlands, and a number of senior positions in the former Organon and Genzyme.

*Shares:* 4,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

***Proposal for election of new members of the board of directors:***

*Håkan Björklund*

Born 1956.

Ph.D. from Karolinska Institutet in Stockholm.

*Other assignments:* Industry Executive at Avista Capital Partners

*Previous appointments:* Dr. Björklund is former CEO of Nycomed and has served as a Member of the Board of Directors of several international life science companies including Alere, Coloplast, Danisco, and Lundbeck. Between 2001 and 2007, he also served as member of the Board of Directors for Biovitrum.

Håkan Björklund is proposed for election both as new member of the board of directors and as the chairman of the board.

*Shares:* 15,800

Independent in relation to the company and its management and in relation to the company's principal shareholders.

*Theresa Heggie*

Born 1960.

B.Sc. from Cornell University, Ithaca, NY, USA.

*Previous appointments:* Previously Ms. Heggie was Chief Strategy & Marketing Officer, Bupa based in the UK, and has had various senior commercial positions at Shire Human Genetic Therapies, formerly TKT, including the roles of Vice President & General Manager, EMEA, Chief Executive Officer, Jerini AG (a Shire acquisition) and Senior Vice President Global Commercial Operations, based internationally. Previously in roles of Vice President Marketing, Vice President Anaesthesia & Critical Care, Europe, and Vice President, Global Marketing Anaesthesia & Critical Care with Baxter – and formerly Ohmeda PPD. Ms. Heggie started her career with Dow Chemical and Janssen Pharmaceuticals.

Ms. Heggie is a Global Business Leader with more than 30 years' experience in healthcare, the majority in pharmaceuticals and biotechnology.

*Shares:* 0

[Independent in relation to the company and its management and in relation to the company's principal shareholders.

*Jeffrey M Jonas*

Born 1953.

M.D. from Harvard Medical School. Residency in Psychiatry at Harvard. B.A., summa cum laude in Biology and English from Amherst College.

*Other appointments:* Since 2013, Dr. Jonas is serving as President & Chief Executive Officer of Sage Therapeutics, Cambridge, MA, USA.

*Previous appointments:* Jeffrey Jonas has served on several boards including Cara Therapeutics. He has also been Senior Vice President Research & Development Pharmaceuticals and President of the Regenerative Medicine Division of Shire plc., Executive Vice President at ISIS Pharmaceuticals and Executive Vice President and Chief Medical Officer at Forest Laboratories. Dr Jonas has also held various positions of increased responsibilities with Upjohn Laboratories. Founder of AVAX Technologies as well as President and Chief Executive Officer and Chairman, President and Chief Technology Officer of SCEPTOR Industries.

Dr. Jonas has in excess of 20 years' of experience on both the science and business sides of the pharmaceutical and healthcare industries. He is well published, is the author of more than a 100 books, scientific articles, and abstract, and has given many academic, business, and industry presentations.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.